Botox for platysma bands: what the FDA-approved neck indication covers

BOTOX Cosmetic—not botulinum toxin as a category—is FDA approved for temporary improvement in the appearance of moderate to severe platysma bands associated with platysma muscle activity in adults. The label addresses a defined muscle-driven finding and injection pattern. It does not approve a generic “neck lift,” treatment of loose skin, horizontal etched lines, submental fat, salivary glands, or another toxin’s use or units.¹²

This narrow wording is useful. It tells a consumer what must be true for the labeled claim to match: exact product, adult patient, moderate-to-severe bands, platysma activity, appearance endpoint, temporary effect, and labeled administration. Change one of those elements and the regulatory description may change.

Platysma bands are a muscle finding, not every aging-neck feature

The platysma is a thin superficial neck muscle. Prominent vertical bands can become more visible with contraction and, for some people, at rest. A consultation should separate them from other structures.

Ask the injector to demonstrate which visible line is an active platysma band and what will remain. If the answer is simply “Botox tightens the neck,” the proposed job is not anatomically defined.

The label belongs to one formulation and one unit system

BOTOX Cosmetic contains onabotulinumtoxinA. Units of biological activity are product-specific and cannot be converted directly to another botulinum toxin product’s units.² A clinic that quotes only “36 units of toxin” has omitted the product.

The current label describes total doses of 26, 31, or 36 BOTOX Cosmetic units based on the presentation of bands and includes injections into vertical bands plus along the jawline within the labeled pattern.² This article does not reproduce an injection map for self-use or prescribe a dose. The practical record is:

• exact product and vial lot;
• reconstitution and final concentration;
• total units and units by site;
• dynamic and resting assessment;
• photographs with consistent expression and lighting;
• concurrent toxin treatment elsewhere and cumulative exposure;
• follow-up date and adverse-effect contact.

FDA approval does not mean risk-free or surgery-equivalent

The label carries the class boxed warning about distant spread of toxin effect and describes contraindications, warnings, precautions, drug interactions, and adverse reactions.² The neck is functionally important for swallowing, speaking, breathing, head position, and facial movement. Review neuromuscular conditions, swallowing or breathing history, prior neck surgery, medicines that may affect neuromuscular transmission, and recent toxin exposure with the licensed prescriber.

Temporary muscle modulation and surgery are not substitutes by default. A neck lift may address skin and platysma through a surgical plan; neck liposuction addresses selected superficial fat; filler or energy devices own other proposed jobs. The neck-liposuction-versus-neck-lift guide maps those layers. A labeled toxin indication does not validate combining every neck modality at once.

Read the trials by endpoint

The pivotal study record identifies the enrolled population, product, injection pattern, comparator, scales, timepoints, sponsor, and eligibility criteria.³ The approved claim is temporary improvement in appearance—not permanent elevation, quantified skin tightening, fat reduction, or prevention of future aging.

When a clinic presents a percentage, ask:

1. Was it investigator-rated, patient-rated, or both?
2. Did assessment occur at maximal contraction, rest, or both?
3. What severity was required at baseline?
4. At what timepoint was the endpoint measured?
5. How many participants completed that timepoint?
6. What harms and exclusions accompanied the result?

Do not transfer results to a different toxin, dilution, dose, injection map, age group, or concern.

Standardized photographs keep the endpoint honest

Platysma-band appearance changes with head angle, camera height, lighting, jaw position, speech and contraction. Baseline and follow-up photographs should include the same views at rest and at maximal contraction under repeatable conditions. A tighter crop, raised chin or softer shadow can create an apparent response without a comparable anatomical change.

Ask when the practice evaluates peak effect and duration and what scale, if any, it uses. The pivotal program assessed defined timepoints and band-severity scales; a social-media clip recorded days after treatment cannot establish the labeled duration or capture later adverse effects.³ Preserve patient-reported function and satisfaction separately from the injector’s appearance rating.

If the clinic offers a no-charge “touch-up,” define the time window, assessment criteria, maximum additional product, and reasons not to add more. Muscle weakness can continue to evolve after injection. Adjustment should not be driven only by a calendar or the desire to use a pre-purchased unit balance.

Combination plans need a component-by-component explanation

A neck package may combine toxin with filler, deoxycholic acid, cryolipolysis, radiofrequency, ultrasound, laser, threads or surgery. Each component should own a different documented target. Layering procedures does not turn the toxin into a skin-tightening or fat-removal treatment, and it can make swelling, weakness, contour change or another adverse effect harder to attribute.

Ask for sequencing, recovery, and stop rules. If the clinician wants to judge the toxin’s effect on dynamic bands before adding another treatment, the reassessment date should be in writing. If surgery is planned, the surgeon should know the product, units, sites and treatment date so the preoperative examination can be interpreted.

“Nefertiti lift” is not the FDA indication name

Practices may use “Nefertiti lift,” “Botox neck lift,” jawline toxin, micro-Botox, or similar labels. Those terms are not standardized procedure definitions. They can refer to different products, targets, doses, planes, and goals. The use may be lawful off-label prescribing by an appropriately licensed clinician, but it should be described accurately.

The off-label-use guide explains the distinction: FDA regulates product marketing and approvals; clinicians may prescribe approved drugs off label within professional practice, but off-label does not mean FDA approved for that use. Marketing should not erase the difference.

Compare complete quotes

Normalize quotes by exact product and total units, not “area.” Include assessment, photography, follow-up, possible adjustment window, excluded units, and management of an adverse effect. A lower total can reflect a narrower pattern, different product, different unit scale, or incomplete treatment rather than better value.

If surgery or another procedure is proposed, compare its distinct target, anesthesia, facility, recovery, scar, follow-up, and revision plan. Do not compare only per-session price with an operation.

The decisive question

Ask: “Which part of my neck is an active platysma band covered by this exact BOTOX Cosmetic label, which parts are not, and what product-specific dose, endpoint, duration, and safety plan are you proposing?” The approval is useful precisely because it is bounded.